Aarti Drugs posts 16.2% YoY PBT growth in Q1 FY26; focuses on capacity expansion, backward integration, and regulated markets.

• EBITDA rose 12% to ₹74.4 crore; margins expanded to 12.6% as specialty, formulations, and API revenue segments grew.
• Capex of ₹48.5 crore focused on the new Sayakha plant for anti-diabetics and the upcoming Salicylic Acid plant at Tarapur.
• USFDA approvals, global tariff shifts create export opportunities as the company eyes a stronger presence in regulated markets.